Payment overview · 2025
General Payments
$39.65
2 reported records · 2 companies
Healthcare provider profile · identity verified
Mohammadullah Faiz, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANTONIO, TX · NPI 1427027036
Verified facts
What the public records show
CMS Open Payments records show Mohammadullah Faiz, M.D. received $39.65 in general payments during 2025 across 2 reported records.
Merck Sharp & Dohme LLC accounted for 62.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.68 | 62.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.97 | 37.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $39.65 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 20 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 483 | 164 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 473 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 412 | 142 |
| Metformin Hcl | Metformin Hcl | 360 | 117 |
| Lisinopril | Lisinopril | 337 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 71 |
| Losartan Potassium | Losartan Potassium | 193 | 69 |
| Simvastatin | Simvastatin | 146 | 48 |
| Tramadol Hcl | Tramadol Hcl | 141 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 43 |
| Gabapentin | Gabapentin | 131 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 131 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 43 |
| Omeprazole | Omeprazole | 122 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 44 |
| Montelukast Sodium | Montelukast Sodium | 115 | 43 |
| Metformin Hcl Er | Metformin Hcl | 103 | 35 |
| Enalapril Maleate | Enalapril Maleate | 102 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 46 |
| Carvedilol | Carvedilol | 87 | 30 |
| Januvia | Sitagliptin Phosphate | 86 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 25 |
| Glipizide | Glipizide | 80 | 25 |
| Sertraline Hcl | Sertraline Hcl | 79 | 27 |
| Eliquis | Apixaban | 75 | 21 |
| Farxiga | Dapagliflozin Propanediol | 74 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 27 |
| Trazodone Hcl | Trazodone Hcl | 65 | 22 |
| Furosemide | Furosemide | 64 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 20 |
| Celecoxib | Celecoxib | 56 | 27 |
| Baclofen | Baclofen | 54 | 24 |
| Alendronate Sodium | Alendronate Sodium | 53 | 17 |
| Ozempic | Semaglutide | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 17 |
| Finasteride | Finasteride | 39 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 13 |
| Jardiance | Empagliflozin | 36 | 11 |
| Nifedipine Er | Nifedipine | 36 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 19 |
| Allopurinol | Allopurinol | 33 | 11 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Alprazolam | Alprazolam | 32 | 11 |
| Prednisone | Prednisone | 32 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | 13 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Ramipril | Ramipril | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Clonazepam | Clonazepam | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $39.65 · 2 records | Merck Sharp & Dohme LLC | CAPVAXIVE, PAXLOVID | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error